Biotech IPOs: Trends for Financing Innovation

Today, there are ~300% more publicly-traded biotech companies than just 25 years ago. Why? Public market investors are more excited by the promise of new medicines curing diseases than ever before.

However, recently, major M&A activity, landmark clinical readouts, and geopolitics have created a highly-dynamic IPO landscape for biotech companies. In this session, co-hosted by Credit Suisse, we discuss the recent market trends and IPO landscape for emerging life sciences companies.

In this webinar, you will learn:

• Biotech market performance in 2019

• Recent events translating into growth in the industry

• Biotech IPO outlook for 2020